1 “... needed to have access to medication support/review, psychological support, and physical function support...”

2 “... difference [SMD] 0.33, 95% CI 0.56 to 0.09) (SOE: low), and risk of surgery at short-term followup (relative...”

3 “... difference [SMD] 0.33, 95% CI 0.56 to 0.09) (SOE: low), and risk of surgery at short-term followup (relative...”

4 “... was the most commonly reported outcome, followed by back-specific function. When present, observed benefits...”

5 “... was the most commonly reported outcome, followed by back-specific function. When present, observed benefits...”

6 “..., there was no difference in pain at intermediate term, but a slight improvement at long term (SOE: low). Psychological...”

7 “..., there was no difference in pain at intermediate term, but a slight improvement at long term (SOE: low). Psychological...”

8

9

10 “...4.9%, RR, 1.47, 95% CI 1.19 to 1.80); other serious harms were infrequent, with no differences...”

11

12 “... to understand long-term benefits, risk of abuse and related outcomes, and effectiveness of different opioid...”

13 “... to understand long-term benefits, risk of abuse and related outcomes, and effectiveness of different opioid...”

14 “... the strength of evidence. Prioritized outcomes included pain, overall function, and adverse events....”

15

16 “...) and few harms relative to older antiviral therapies. An SVR after antiviral therapy is associated...”

17 “...) and few harms relative to older antiviral therapies. An SVR after antiviral therapy is associated...”

18 “... small decrease in pain severity (7 RCTs, N=632, 0 to 10 scale, mean difference [MD] −0.54, 95...”

19 “... tool may not have the capacity to provide all desired functionalities, and each tool has differing...”

20 “... tool may not have the capacity to provide all desired functionalities, and each tool has differing...”